Opening Address & Keynote Presentation by Ablexis and AlivaMab Biologics. Driven by Diversity: AlivaMab' Platforms Fuel Biologics Discovery for Complex Targets
17 Jun 2024
Salon H
Target Selection
,
Lead Identification & Optimization
,
Formats & Scaffolds
,
Bi/Multispecifics
,
Emerging Technologies
![Opening Address & Keynote Presentation by Ablexis and AlivaMab Biologics. Driven by Diversity: AlivaMab' Platforms Fuel Biologics Discovery for Complex Targets](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/experts/Ablexis-Alivamab-Stacked-Logo.png/fit-in/1500x9999/filters:no_upscale())
Successful biologics development hinges on innovative strategies for generating diversity in antibody discovery. With an ever-growing suite of AlivaMab® Mouse strains and creative ‘fit-for-purpose’ strategies, Ablexis and AlivaMab Biologics are delivering diverse panels of lead-quality antibodies. Here, we will highlight how diverse AlivaMab Mouse strains and discovery processes enable successful discovery of diverse panels for CLC, human single-domain, membrane multispanners, CD3, and TCRm antibodies.